Alternate-day fasting reverses the age-associated hypertrophy phenotype in rat heart by influencing the ERK and PI3K signaling pathways

Mechanisms of Ageing and Development

Volumn 132, Issue 6-7, 2011, Pages 305-314

  Castello, Laura ^a   Maina, Marco ^b   Testa, Gabriella ^b   Cavallini, Gabriella ^c   Biasi, Fiorella ^b   Donati, Alessio ^c   Leonarduzzi, Gabriella ^b   Bergamini, Ettore ^c   Poli, Giuseppe ^b   Chiarpotto, Elena ^b  

^a Pediatric Oncohematology   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Alternate day fasting; ERK; Heart; Hypertrophy; PI3K

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA;

AGING; ALTERNATE DAY FASTING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FAILURE; HEART HYPERTROPHY; MALE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMEGALY; FASTING; LONGEVITY; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, SPRAGUE-DAWLEY; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MACACA MULATTA; RATTUS; RODENTIA;

EID: 79961211386     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2011.06.006     Document Type: Article

References (81)

1. Anderson R.M., Shanmuganayagam D., Weindruch R. Caloric restriction and aging studies in mice and monkeys. Toxicol. Pathol. 2009, 37:47-51.
2. Anson R.M., Jones B., De Cabo R. The diet restriction paradigm: a brief review of the effects of every-other-day feeding. Age 2005, 27:17-25.
3. Aoyagi T., Izumo S. Hemodynamic overload-induced activation of myocardial mitogen-activated protein kinases in vivo: augmented responses in young spontaneously hypertensive rats and diminished responses in aged Fischer 344 rats. Hypertension 2001, 37:52-57.
4. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 2003, 21:3-12.
5. Berni R., Savi M., Bocchi L., Delucchi F., Musso E., Chaponnier C., Gabbiani G., Clement S., Stilli D. Modulation of actin isoform expression before the transition from experimental compensated pressure-overload cardiac hypertrophy to decompensation. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1625-H1632.
6. Boengler K., Hilfiker-Kleiner D., Drexler H., Heusch G., Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol. Ther. 2008, 120:172-185.
7. Booz G.W., Day J.N., Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J. Mol. Cell. Cardiol. 2002, 34:1443-1445.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
9. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., Hewett T.E., Jones S.P., Lefer D.J., Peng C.F., Kitsis R.N., Molkentin J.D. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000, 19:6341-6350.
10. Carrier L., Boheler K.R., Chassagne C., de la Bastie D., Wisnewsky C., Lakatta E.G., Schwartz K. Expression of the sarcomeric actin isogenes in the rat heart with development and senescence. Circ. Res. 1992, 70:999-1005.
11. Castello L., Froio T., Cavallini G., Biasi F., Sapino A., Leonarduzzi G., Bergamini E., Poli G., Chiarpotto E. Calorie restriction protects against age-related rat aorta sclerosis. FASEB J. 2005, 19:1863-1865.
12. Castello L., Froio T., Maina M., Cavallini G., Biasi F., Leonarduzzi G., Donati A., Bergamini E., Poli G., Chiarpotto E. Alternate-day fasting protects the rat heart against age-induced inflammation and fibrosis by inhibiting oxidative damage and NF-kB activation. Free Radic. Biol. Med. 2010, 48:47-54.
13. Cheng X.W., Okumura K., Kuzuya M., Jin Z., Nagata K., Obata K., Inoue A., Hirashiki A., Takeshita K., Unno K., Harada K., Shi G.P., Yokota M., Murohara T. Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J. Cardiovasc. Pharmacol. 2009, 54:47-56.
14. Clerk A., Aggeli I.K., Stathopoulou K., Sugden P.H. Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes. Cell Signal. 2006, 18:225-235.
15. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W., Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
16. Dhahbi J.M., Tsuchiya T., Kim H.J., Mote P.L., Spindler S.R. Gene expression and physiologic responses of the heart to the initiation and withdrawal of caloric restriction. J. Gerontol. A: Biol. Sci. Med. Sci. 2006, 61:218-231.
17. Dolinsky V.W., Morton J.S., Oka T., Robillard-Frayne I., Bagdan M., Lopaschuk G.D., Des Rosiers C., Walsh K., Davidge S.T., Dyck J.R. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010, 56:412-421.
18. Dorn G.W. II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007, 49:962-970.
19. Ferrara N., Davia K., Abete P., Rengo F., Harding S.E. Alterations in beta-adrenoceptor mechanisms in the aging heart. Relationship with heart failure. Aging (Milano) 1997, 9:391-403.
20. Fischer P., Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br. J. Pharmacol. 2008, 153(Suppl. 1):S414-S427.
21. Fredj S., Bescond J., Louault C., Delwail A., Lecron J.C., Potreau D. Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J. Cell. Physiol. 2005, 204:428-436.
22. Frey N., Katus H.A., Olson E.N., Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 2004, 109:1580-1589.
23. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., Gardin J.M., Rutledge J.E., Boineau R.C. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J. Am. Coll. Cardiol. 2000, 35:1628-1637.
24. Gradman A.H., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog. Cardiovasc. Dis. 2006, 48:326-341.
25. Hacker T.A., McKiernan S.H., Douglas P.S., Wanagat J., Aiken J.M. Age-related changes in cardiac structure and function in Fischer 344×Brown Norway hybrid rats. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H304-H311.
26. Hattori R., Maulik N., Otani H., Zhu L., Cordis G., Engelman R.M., Siddiqui M.A., Das D.K. Role of STAT3 in ischemic preconditioning. J. Mol. Cell Cardiol. 2001, 33:1929-1936.
27. Heilbronn L.K., Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am. J. Clin. Nutr. 2003, 78:361-369.
28. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell. Biol. 2006, 7:589-600.
29. Holloszy J.O., Fontana L. Caloric restriction in humans. Exp. Gerontol. 2007, 42:709-712.
30. Hursting S.D., Lavigne J.A., Berrigan D., Perkins S.N., Barrett J.C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 2003, 54:131-152.
31. Iemitsu M., Miyauchi T., Maeda S., Sakai S., Kobayashi T., Fujii N., Miyazaki H., Matsuda M., Yamaguchi I. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R2029-R2036.
32. Inuzuka Y., Okuda J., Kawashima T., Kato T., Niizuma S., Tamaki Y., Iwanaga Y., Yoshida Y., Kosugi R., Watanabe-Maeda K., Machida Y., Tsuji S., Aburatani H., Izumi T., Kita T., Shioi T. Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation 2009, 120:1695-1703.
33. Izumi Y., Kim S., Murakami T., Yamanaka S., Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension 1998, 31:50-56.
34. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S., Gao Q., Chai G.X., Ji L., Iwamoto Y., Li E., Schneider M., Russell K.S., Fu X.Y. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12929-12934.
35. Jain N., Zhang T., Fong S.L., Lim C.P., Cao X. Repression of STAT3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 1998, 17:3157-3167.
36. Johnston J.A. Are SOCS suppressors, regulators, and degraders?. J. Leukoc. Biol. 2004, 75:743-748.
37. Kass D.A. Age-related changes in ventricular-arterial coupling: pathophysiologic implications. Heart Fail. Rev. 2002, 7:51-62.
38. Kawaguchi M., Hay I., Fetics B., Kass D.A. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714-720.
39. Kennedy R.A., Kemp T.J., Sugden P.H., Clerk A. Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes. J. Mol. Cell. Cardiol. 2006, 41:236-247.
40. Klemola R., Huttunen P., Laine M., Weckstrom M., Hirvonen J. Catecholamines in pericardial fluid of normotensive, spontaneously hypertensive and reserpine-treated rats. Acta Physiol. Scand. 1999, 165:293-297.
41. Ko H.J., Zhang Z., Jung D.Y., Jun J.Y., Ma Z., Jones K.E., Chan S.Y., Kim J.K. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009, 58:2536-2546.
42. Kong S.W., Bodyak N., Yue P., Liu Z., Brown J., Izumo S., Kang P.M. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol. Genomics 2005, 21:34-42.
43. Kopelman P. Health risks associated with overweight and obesity. Obes. Rev. 2007, 8:13-17.
44. Kunisada K., Negoro S., Tone E., Funamoto M., Osugi T., Yamada S., Okaba M., Kishimoto T., Yamauchitakihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:315-319.
45. Lakatta E.G. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003, 107:490-497.
46. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a " set up" for vascular disease. Circulation 2003, 107:139-146.
47. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346-354.
48. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
49. MacLellan W.R., Lee T.C., Schwartz R.J., Schneider M.D. Transforming growth factor-beta response elements of the skeletal alpha-actin gene. Combinatorial action of serum response factor, YY1, and the SV40 enhancer-binding protein, TEF-1. J. Biol. Chem. 1994, 269:16754-16760.
50. Martin B., Ji S., Maudsley S., Mattson M.P. " Control" laboratory rodents are metabolically morbid: why it matters. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6127-6133.
51. McKinsey T.A., Kass D.A. Small-molecule therapies for cardiac hypertrophy moving beneath the cell surface. Nat. Rev. Drug Discov. 2007, 6:617-635.
52. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., Izumo S. Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12355-12360.
53. Minami J., Nishikimi T., Ishimitsu T., Makino Y., Kawano Y., Takishita S., Kangawa K., Matsuoka H. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension. J. Cardiovasc. Pharmacol. 2000, 36:S83-S86.
54. Nascimento A.F., Sugizaki M.M., Leopoldo A.S., Lima-Leopoldo A.P., Nogueira C.R., Novelli E.B., Padovani C.R., Cicogna A.C. Misclassification probability as obese or lean in hypercaloric and normocaloric diet. Biol. Res. 2008, 41:253-259.
55. Ni C.W., Hsieh H.J., Chao Y.J., Wang D.L. Shear flow attenuates serum-induced STAT3 activation in endothelial cells. J. Biol. Chem. 2003, 278:19702-19708.
56. Niemann B., Chen Y., Issa H., Silber R.-E., Rohrbach S. Caloric restriction delays cardiac ageing in rats: role of mitochondria. Cardiovasc. Res. 2010, 88:267-276.
57. Nishikawa K., Yoshida M., Kusuhara M., Ishigami N., Isoda K., Miyazaki K., Ohsuzu F. Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H176-H183.
58. Okin P.M., Devereux R.B., Harris K.E., Jern S., Kjeldsen S.E., Julius S., Edelman J.M., Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann. Intern. Med. 2007, 147:311-319.
59. O'Neill B.T., Abel E.D. Akt1 in the cardiovascular system: friend or foe?. J. Clin. Invest. 2005, 115:2059-2064.
60. Osadchii O., Norton G., Deftereos D., Woodiwiss A. Rat strain-related differences in myocardial adrenergic tone and the impact on cardiac fibrosis, adrenergic responsiveness and myocardial structure and function. Pharmacol. Res. 2007, 55:287-294.
61. Parker T.G., Packer S.E., Schneider M.D. Peptide growth factors can provoke " fetal" contractile protein gene expression in cardiac myocytye hypertrophy. J. Clin. Invest. 1990, 85:507-514.
62. Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., Marengo S., Russo G., Azzolino O., Rybalkin S.D., Silengo L., Altruda F., Wetzker R., Wymann M.P., Lembo G., Hirsch E. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004, 118:375-387.
63. Peterson G.L. Determination of total protein. Methods Enzymol. 1983, 91:95-119.
64. Podewski E.K., Hilfiker-Kleiner D., Hilfiker A., Morawietz H., Lichtenberg A., Wollert K.C., Drexler H. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003, 107:798-802.
65. Redman L.M., Heilbronn L.K., Martin C.K., Alfonso A., Smith S.R., Ravussin E., Pennington C.T. Effect of calorie restriction with or without exercise on body composition and fat distribution. J. Clin. Endocrinol. Metab. 2007, 92:865-872.
66. Schwartz K., de la Bastie D., Bouveret P., Oliviero P., Alonso S., Buckingham M. α-Skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ. Res. 1986, 59:551-555.
67. Schwarz J.B., Zipes Douglas P. Cardiovascular disease in the elderly. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2005, 1925-1949. W.B. Saunders, Philadelphia. P. Zipes Douglas, E. Braunwald (Eds.).
68. Smith R.M., Suleman N., Lacerda L., Opie L.H., Akira S., Chien K.R., Sack M.N. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc. Res. 2004, 63:611-616.
69. Stauss H.M., Mrowka R., Nafz B., Patzak A., Unger T., Persson P.B. Does low frequency power of arterial blood pressure reflect sympathetic tone?. J. Auton. Nerv. Syst. 1995, 54:145-154.
70. Stern J.S., Gades M.D., Wheeldon C.M., Borchers A.T. Calorie restriction in obesity: prevention of kidney disease in rodents. J. Nutr. 2001, 131:913S-S917.
71. Stilli D., Bocchi L., Berni R., Zaniboni M., Cacciani F., Chaponnier C., Musso E., Gabbiani G., Clément S. Correlation of alpha-skeletal actin expression, ventricular fibrosis and heart function with the degree of pressure overload cardiac hypertrophy in rats. Exp. Physiol. 2006, 91:571-580.
72. Suurmeijer A.J., Clement S., Francesconi A., Bocchi L., Angelini A., Van Veldhuisen D.J., Spagnoli L.G., Gabbiani G., Orlandi A. α-Actin isoform distribution in normal and failing human heart: a morphological, morphometric, and biochemical study. J. Pathol. 2003, 199:387-397.
73. Susic D., Frohlich E.D. The aging hypertensive heart: a brief update. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:104-110.
74. Vesely D.L., de Bold A.J. Cardiac natriuretic peptides gene expression and secretion in inflammation. J. Investig. Med. 2009, 57:29-32.
75. Walford R.L., Mock D., Verdery R., MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:B211-B224.
76. Wan R., Camandola S., Mattson M.P. Intermittent food deprivation improves cardiovascular and neuroendocrine responses to stress in rats. J. Nutr. 2003, 133:1921-1929.
77. Weber K.T. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol. 2000, 15:264-272.
78. Weindruch R., Sohal R.S. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N. Engl. J. Med. 1997, 337:986-994.
79. Wormald S., Hilton D.J. Inhibitors of cytokine signal transduction. J. Biol. Chem. 2004, 279:821-824.
80. Yaspelkis B.B., Kvasha I.A., Lessard S.J., Rivas D.A., Hawley J.A. Aerobic training reverses high-fat diet-induced pro-inflammatory signalling in rat skeletal muscle. Eur. J. Appl. Physiol. 2010, 110:779-788.
81. Yasukawa H., Hoshijima M., Gu Y., Nakamura T., Pradervand S., Hanada T., Hanakawa Y., Yoshimura A., Ross J., Chien K.R. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J. Clin. Invest. 2001, 108:1459-1467.